Regulatory Information
HYPHENS PHARMA PTE. LTD.
HYPHENS PHARMA PTE. LTD.
Therapeutic
Prescription Only
Formulation Information
TABLET, FOR SOLUTION
**4.2. Posology and method of administration** Elderly and adults above 18 years: Oral formulations: Posology _300 mg hard capsules:_ 1 capsule 2–3 times a day, for oral use. _300 mg dispersible tablets:_ 1 tablet 2–3 times a day, for oral use. Method of administration for _dispersible tablets_ The tablets should be dissolved in a glass of water. The dispersion should be stirred with a spoon and drunk immediately. The score-line on the tablet does not divide the tablet into equal half-doses.
ORAL
Medical Information
**4.1. Therapeutic indications** Mucolytic agent for use in adults with acute and chronic respiratory disorders (including chronic obstructive pulmonary disease, acute exacerbations of chronic obstructive pulmonary disease, rhinosinusitis, pharingolaryngotracheitis, acute and chronic bronchitis) associated with excessive mucus production.
**4.3. Contra-indications** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Patients with active peptic ulcer. Because of a possible interference of the product metabolites with methionine metabolism, ERDOMED is contraindicated in patients suffering from hepatic cirrhosis and deficiency of the cystathionine-synthetase enzyme. **Since there are no data in patients with renal failure with creatinine clearance < 25 ml/min or with severe liver failure, the use of erdosteine is not recommended in these patients.** The drug is contraindicated in children younger than 2 years (oral forms).
R05CB15
erdosteine
Manufacturer Information
HYPHENS PHARMA PTE. LTD.
EDMOND PHARMA S.R.L
Active Ingredients
Documents
Package Inserts
Erdomed PI.pdf
Approved: November 5, 2019